Sarina Tanimoto's departure as Chief Medical Officer of ARS Pharmaceuticals, Inc. was reported; the filing names no successor. As of November 6, 2026, ARS Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 13, 2026 to July 17, 2026, naming 2 departures (Form 8-K, July 17, 2026).
Who owns ARS Pharmaceuticals, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like ARS Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Richard Lowenthal · Role: Director · 8-K, 2026-07-17
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-07
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-13
ARS Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-13 to 2026-07-17. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as ARS Pharmaceuticals, Inc. files it.
Also on the record for ARS Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.3% of the class | 5%+ stakes | Source |
| July 14, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 2.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Rubric Capital Management LP | 8.06% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.98% of the class | 5%+ stakes | Source |
| March 31, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 6% of the class | 5%+ stakes | Source |
| March 24, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.4% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by Rubric Capital Management LP | 6.27% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.1% of the class | 5%+ stakes | Source |
| October 1, 2025 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 11.1% of the class | 5%+ stakes | Source |
| August 1, 2025 | Stake report, Schedule 13D/A, by James E. Flynn | 7.75% of the class | 5%+ stakes | Source |
| July 22, 2025 | Stake report, Schedule 13D/A, by James E. Flynn | 8.79% of the class | 5%+ stakes | Source |
| July 2, 2025 | Stake report, Schedule 13D/A, by James E. Flynn | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs ARS Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on ARS Pharmaceuticals, Inc. and the records around it.
ARS Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Companies that share a holder
- Deerfield Mgmt III, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch ARS Pharmaceuticals, Inc.
Get an email when ARS Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ARS Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ARS Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ARS Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-17 | Out | Director | 8-K, 2026-07-17 | ||
| 2026-07-17 | Out | Chief Medical Officer | 8-K, 2026-07-17 | ||
| 2026-07-07 | Reported | not named in the filing | 8-K, 2026-07-07 | ||
| 2026-05-13 | Reported | not named in the filing | 8-K, 2026-05-13 |
Who leads ARS Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Sarina Tanimoto, departure reported (filed 2026-07-17). No successor is named in these filings.
- Director: Richard Lowenthal, departure reported (filed 2026-07-17). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on ARS Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at ARS Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at ARS Pharmaceuticals, Inc.Every change, in the filing's words
Departing: Richard Lowenthal, Director
On July 15, 2026, Richard Lowenthal resigned as a member of the Board of Directors (the "Board") of ARS Pharmaceuticals, Inc. (the "Company"), effective immediately.
Departing: Sarina Tanimoto, Chief Medical Officer
Additionally, on July 15, 2026, Sarina Tanimoto, M.D., the Company's Chief Medical Officer, ceased employment with the Company under conditions constituting a termination without cause.
- Mr. Lowenthal's resignation from the Board was a condition of his right to receive severance compensation pursuant to the terms of his employment agreement with the Company and the Company's Change in Control and Severance Benefit Plan, as described under the heading "Employment, Severance, and Change in Control Agreements" in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 29, 2026 (the "Proxy Statement").
- In addition to the severance benefits described in the Proxy Statement, the Company agreed to pay Mr. Lowenthal and Dr. Tanimoto an additional one-time payment of $217,350 and $111,780, respectively, representing a prorated amount of their respective target bonus for 2026.
- These payments and the severance benefits described in the Proxy Statement are conditioned on the effectiveness of the release of claims provided by each of Mr. Lowenthal and Dr. Tanimoto to the Company.
Reported
On July 7, 2026, the Board of Directors (the "Board") of ARS Pharmaceuticals, Inc. (the "Company") appointed the Company's current President Donn Casale as the Company's Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.
- Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company's 2029 annual meeting of stockholders.
- Mr. Lowenthal was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.
Reported
On May 12, 2026, the Board of Directors of ARS Pharmaceuticals, Inc., a Delaware corporation (the "Company"), based in part on the recommendation of Richard Lowenthal, the Company's Chief Executive Officer, appointed Donn Casale as the Company's President effective as of the date he commences employment with the Company, which date is expected to be June 1, 2026.
- Mr. Casale, age 53, has over 25 years of experience in the biopharmaceutical industry.
- Mr. Casale previously worked at Dynavax Technologies, Inc. (acquired by Sanofi in 2026) from October 2017 to May 2026 in roles of increasing responsibility, most recently serving as Chief Commercial Officer since January 2023.
- Prior to joining Dynavax Technologies, Inc., Mr. Casale worked at Depomed, Inc. from March 2014 to October 2017, most recently serving as Director, Marketing.
- Mr. Casale started his career at Merck & Co., Inc., where he served in various positions from January 2000 to March 2014.
- Mr. Casale holds a bachelor's degree in political science from the California Polytechnic State University - San Luis Obispo.
- In connection with his anticipated employment with the Company and appointment as the Company's President, the Company entered into an employment agreement with Mr. Casale (the "Employment Agreement"), which sets forth the terms of Mr. Casale's employment with the Company.
- Pursuant to the Employment Agreement, Mr. Casale will be entitled to receive an annual base salary of $575,000 and will be eligible to earn an annual discretionary bonus of 45% of his then-current annual base salary.
Tools for this story
Each opens in a new tab, filled in for ARS Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.